# Sermorelin Research: GH/IGF-1 Data and the Regenerative Frontier | Sermorelin > Sermorelin research record: pediatric growth-velocity data, the reversal of age-related GH/IGF-1 decline, side effects, and the regenerative-frontier signals. Every claim cited. Confirmed human GH/IGF-1 findings, tagged side-effect data, and the hypothesis-generating regenerative and oncology signals — kept in separate tiers. ## Before the details This page logs sermorelin research in two tiers, kept apart on purpose. The confirmed tier is human data: it made short children grow faster, and it pushed older men's growth-hormone levels back toward youthful ranges. The frontier tier is early, lab-and-computer work — GHRH-style molecules helping skin cells heal, a heart-repair signal, and a computer model flagging sermorelin against a brain tumor. The frontier results are interesting and clearly marked as hypotheses, not proof. Reading them as cures is exactly the mistake this record is built to prevent. ## What the research describes: studied effects of sermorelin The confirmed sermorelin record is an endocrine one: it raises growth hormone and IGF-1, and in the right population that translates into measurable outcomes. In prepubertal GH-deficient children, once-daily subcutaneous GHRH(1-29) raised first-year height velocity from about 4.1 cm/year to roughly 7-8 cm/year, without excessive IGF-1 generation [4]. In healthy older men, GHRH(1-29) twice daily for 14 days produced dose-related GH and IGF-1 increases and, at the high dose, restored those parameters to a young-adult range [5]. The adjacent claims — body composition, cognition, sleep — are real research areas, but the strongest controlled data in several of them were generated with the stabilized analog tesamorelin, not native sermorelin. The [sermorelin vs tesamorelin](/vs-tesamorelin) page handles that attribution. Framed honestly, the 'benefits' of sermorelin are 'studied effects on the GH/IGF-1 axis,' not proven anti-aging outcomes. ## Does sermorelin raise IGF-1? Yes — by stimulating GH, sermorelin raises hepatic IGF-1. In older men, 14 days of GHRH(1-29) produced dose-related IGF-1 increases [5]; the related GHRH analog tesamorelin raised IGF-1 by 117% within the physiologic range in a cognition trial [11]. ## Does sermorelin affect the brain? GHRH administration had a favorable effect on cognition in a randomized trial of older adults, including those with mild cognitive impairment, and modulated brain GABA levels as a neurochemical correlate [11]. These trials used the GHRH analog tesamorelin. ## Can GHRH improve cognition in older adults? In a 20-week randomized, double-blind, placebo-controlled trial of 152 older adults (66 with mild cognitive impairment), a daily GHRH analog had a favorable effect on cognition — executive function P=0.005 — alongside a 117% IGF-1 rise and a 7.4% reduction in body fat [11]. ## Does sermorelin build muscle? GH/IGF-1-axis modulation is discussed as a candidate strategy against age-related muscle loss (sarcopenia), but sermorelin is not an established muscle-building agent; lean-mass effects in healthy adults are not robustly demonstrated [2]. ## Does sermorelin work? In studied populations it raises GH and IGF-1: GHRH(1-29) accelerated growth in GH-deficient children [4] and reversed age-related GH/IGF-1 declines in older men [5]. Adult anti-aging and body-composition claims outpace the rigorous long-term evidence [2]. ## How quickly does sermorelin act? Pharmacologically, a single dose raises serum GH within minutes and keeps it elevated for roughly 3 hours despite a ~10-12 minute plasma half-life [3]. Endocrine endpoints like IGF-1 were measured over days-to-weeks of dosing in the trials [5]. ## The regenerative frontier: GHRH-agonist analogs This is the angle this record was dealt, and it is tagged as frontier throughout. Agonistic analogs of GHRH (MR-409 and MR-502) promoted wound healing by stimulating proliferation and survival of human dermal fibroblasts through ERK and AKT pathways, in an IGF-1-receptor-independent manner; topical MR-409 accelerated wound closure in vivo in a dose-dependent way, with fibroblast proliferation increased more than 50% in vitro [6]. A separate study described a therapeutic approach to heart failure after myocardial infarction based on targeting the GHRH receptor, supporting cardiac-repair interest in GHRH agonists [7]. A 2025 review surveys GHRH-analog development across cancer, regenerative medicine, and metabolic disorders [9]. These are preclinical and review-level signals — not approved sermorelin uses, and not clinical evidence in humans. ## The in-silico glioma signal: a hypothesis, not a treatment A transcriptomic, high-throughput drug-screening study of 1,018 glioma patients identified recurrent glioma as most sensitive to sermorelin in silico, with the signal strongest in high-grade, IDH-wildtype, 1p/19q non-codeleted tumors [8]. This is a computational drug-repurposing finding — sermorelin flagged by a drug-sensitivity score, with a proposed mechanism via cell-cycle blockade and immune modulation. It is hypothesis-generating only. It is not a clinical trial of sermorelin in glioma, and it does not establish that sermorelin treats cancer; popular summaries frequently blur that distinction [8]. ## Sermorelin side effects and tolerability in the research literature Across the published literature, reported sermorelin side effects are generally mild — injection-site reactions are the commonly noted local effect, and the older-men study reported no effect on fasting glucose [5]. The larger concerns are not acute toxicity but two structural caveats. First, rigorous long-term efficacy and safety data for adult secretagogue use are limited; an Annals of Internal Medicine editorial judged GH-secretagogue use for aging 'not yet ready for prime time' [2]. Second, because GH and IGF-1 are mitogenic (they drive cell division), chronically raising them is theorized to carry an oncologic risk — a recognized safety consideration for any GH-axis intervention, even one that works through the body's own feedback-regulated secretion [2]. Sermorelin is also prohibited in sport: GH secretagogues, including GHRH analogs, appear on the WADA Prohibited List, and dedicated detection methods exist. --- A near-black terminal record of the sermorelin literature — GHRH(1-29) traced from receptor to IGF-1, each datum logged to its source and tagged by tier, with the confirmed human data kept apart from the regenerative and in-silico frontier signals; no clinic behind the console and nothing here dispensed or sold.